Most people who arrive at Within Center didn’t come looking for ketamine. They came looking for psilocybin, or MDMA, or ayahuasca, or DMT. They read Michael Pollan’s book or watched a documentary or had a friend come back from a Costa Rican retreat with a different look in their eyes. They started searching, and somewhere along the way the search led them to ketamine. They want to know whether they’ve settled or whether they’ve actually found the thing they were looking for.
This piece is for that person. We’ll walk through what each of these medicines does, where they overlap, where they don’t, and what the legal landscape actually looks like in 2026 — without overpromising and without dismissing.
The medicines, briefly
The five most-discussed medicines in the psychedelic-therapy conversation each have a distinct character. They’re often grouped together because they share a few things: they all alter ordinary consciousness, they all show meaningful clinical effects on depression, anxiety, trauma, or addiction, and they all seem to work, at least in part, by promoting neuroplasticity. But the felt experiences are genuinely different, and so is the legal status of each.
Ketamine
A dissociative anesthetic that produces, at therapeutic doses, an altered state often described as deeply restful, expansive, and sometimes visionary. The medicine itself lasts forty-five minutes to an hour, with a longer integration tail. It’s the only psychedelic-adjacent medicine that has been legal for clinical use in the United States for decades — first as an anesthetic, more recently in psychiatric practice.
Psilocybin
The active compound in “magic mushrooms.” A classical serotonergic psychedelic. Sessions typically last four to six hours and produce visual phenomena, deep emotional opening, and ego-dissolution experiences. Psilocybin has been the subject of major clinical trials at Johns Hopkins, Imperial College London, and elsewhere, with strong results for treatment-resistant depression. It’s currently a Schedule I substance federally, but Oregon and Colorado have created supervised, legal access programs at the state level.
MDMA
Often called an empathogen rather than a classic psychedelic. MDMA produces feelings of safety, openness, and emotional connection that have made it especially promising for PTSD therapy. The MAPS Phase 3 trials produced strong results, but in 2024 the FDA declined to approve MDMA-assisted therapy, asking for additional data. As of mid-2026, MDMA remains Schedule I and is not legally available outside of research settings.
Ayahuasca & DMT
Ayahuasca is a brewed plant medicine traditional to the Amazon basin; DMT is its primary psychoactive compound. The experience is intense, often visionary, and typically lasts thirty minutes (DMT) or four to six hours (ayahuasca). Both are federally illegal in the United States outside of certain religious-use exemptions. Most people who pursue them travel to South America or to ceremonial communities operating quasi-legally.
Ibogaine
A long-acting psychedelic from the iboga plant, used clinically in some countries for opioid addiction. Sessions can last twelve to thirty-six hours. Cardiac risks make it the most medically demanding medicine on this list. Federally illegal in the U.S.; legal in Mexico, Canada, and several other countries.
What they have in common
Cut through the differences and there’s a striking convergence. All of these medicines, including ketamine, appear to do something similar at the neurobiological level: they trigger a period of heightened plasticity in which the brain becomes more open to forming new connections, revising old patterns, and learning emotionally in ways it usually can’t.
A 2022 review in Nature mapped the overlapping mechanisms across psychedelics and ketamine, finding remarkable similarity in how they remodel synapses and shift the activity of the default mode network — the brain network associated with self-referential thinking, rumination, and the rigid self-narratives that drive depression and anxiety.
The clinical evidence converges, too. Major trials of psilocybin for depression have shown effects roughly four times the size of standard antidepressants. Ketamine has produced similar results for treatment-resistant depression. MDMA produced large reductions in PTSD symptoms in MAPS’s Phase 3 trials. The medicines differ in flavor, but they’re aiming at something similar: opening the brain’s capacity to change, then trusting the right experience inside that opening to do the work.
The medicines differ in flavor, but they’re aiming at something similar — opening the brain’s capacity to change, then trusting the right experience to do the work.
Where they’re different
The differences matter, and they’re not just academic. The texture of the experience, the length, the level of guidance required, and what the medicine is best suited to working on all vary.
| Medicine | Duration | Character of experience | Particularly suited for |
|---|---|---|---|
| Ketamine | 45–60 min | Dissociative, restful, sometimes visionary; less ego-disruptive than classical psychedelics | Depression, anxiety, suicidal ideation, treatment resistance |
| Psilocybin | 4–6 hours | Visual, emotionally cathartic, ego-dissolving | Existential distress, end-of-life work, depression |
| MDMA | 4–6 hours | Heart-opening, safety-producing, lucid | PTSD, attachment work, couples therapy |
| Ayahuasca | 4–6 hours | Visionary, often somatic; physically intense | Spiritual seeking, deep grief, addiction |
| Ibogaine | 12–36 hours | Life-review, often relentless; medically intense | Opioid addiction (with cardiac screening) |
Two practical differences are worth dwelling on.
Length. A ketamine ceremony is short. A psilocybin or MDMA session is most of a day. A 30-minute DMT experience is over before you’ve adjusted to the room. Length isn’t better or worse, but it has implications. Shorter medicines mean lower-stakes individual sessions, easier scheduling, and the possibility of a series — six ketamine ceremonies over six weeks is an entirely different therapeutic arc than one psilocybin session a year. Longer medicines tend toward a single, longer, more-singular experience.
Intensity. Ketamine is generally the gentlest of the psychedelic-adjacent medicines. The experience is dissociative rather than ego-disrupting; people typically feel held at a slight remove from their ordinary self rather than dissolved into something larger. Many people who would find a psilocybin journey overwhelming find ceremonial ketamine workable. This is not a small thing — the difference between a medicine that can be repeated comfortably and one that asks a great deal each time changes who can use it and how.
The legal reality
Here’s the part most reading on the internet gets either wrong or scrubbed clean of nuance.
As of 2026, ketamine is the only psychedelic-adjacent medicine legally and routinely available for psychiatric use in the United States. Psilocybin has supervised legal access in Oregon and Colorado, and several cities have decriminalized possession, but no FDA approval yet exists. MDMA was rejected by the FDA in 2024; the path forward is now uncertain. DMT and ibogaine remain federally illegal. The Trump administration’s 2026 executive order on psychedelics directed federal agencies to fast-track research and FDA review, which may shift this picture in the next two to four years — but it has not yet shifted the picture today.
What this means practically: someone who wants psychedelic-assisted therapy, today, in the United States, has three honest options. Travel to a foreign jurisdiction where another medicine is legal. Wait for FDA approval, which may or may not come on the timeline anyone hopes. Or work with ketamine, which is here, now, and has the most clinical evidence behind it of any medicine in this entire category.
Is ketamine a substitute, or is it the thing itself?
This is the question worth dwelling on, because the framing matters.
If you’ve read enough Michael Pollan to be enthusiastic about psilocybin and you find yourself in a ketamine clinic because that’s what’s available, it’s easy to feel like you’re settling. You’re not getting the “real” medicine, just an acceptable cousin. We don’t think this is the right way to look at it.
Ketamine is not a substitute psilocybin. It’s its own medicine, with its own character, and in some ways it’s actually a better fit for many of the people who come asking. It’s gentler. It’s shorter. It can be done in series, which means trauma and depression can be approached gradually rather than confronted in a single all-day session. It has the longest clinical track record of any medicine in this category. And the neurobiological “window” it opens — the period of heightened plasticity afterward — is real, well-documented, and substantial.
The thing that actually does the healing in any psychedelic-assisted therapy isn’t the molecule alone. It’s the molecule plus the container plus the integration plus the willingness of the person doing the work. Ketamine, given in ceremony, supports all of those just as well as any other medicine in this family. Sometimes better, because the gentler character means people can stay engaged with the work rather than spending a year recovering from a single intense experience.
If you’re still curious about psilocybin
We tell people this honestly: if you have a strong intuition that psilocybin specifically is the medicine you’re looking for, that intuition is worth honoring. Some people’s nervous systems are calling them toward something visual and embodied that ketamine doesn’t produce in quite the same way. Oregon’s legal access program is real and operating. Some people travel for it. Others wait.
What we don’t recommend is dismissing ketamine because it isn’t psilocybin. That’s like dismissing acupuncture because it isn’t massage. Different tools, both real, both effective, neither one a discount version of the other.
For most of the people who walk in our doors — people with treatment-resistant depression, anxiety that won’t loosen, trauma they’re tired of carrying, decades of medication that hasn’t fully worked — ceremonial ketamine, held in a real container with real preparation and real integration, is exactly what they were looking for. They just didn’t know the name of it yet.
If you’re trying to figure out whether this work fits you, the most useful thing is a real conversation with someone who can hear what you’re actually asking for. We’d be glad to be that conversation.